Scarica l'app Stockscreener
1.52
4.40%
-0.07
Dopo l'orario di chiusura:
1.52
Atai Life Sciences N V Borsa (ATAI) Ultime notizie
Atai Life Sciences stock target cut, retains buy rating on developments - Investing.com
Oxbridge Re Holdings Among 3 US Penny Stocks To Watch - Simply Wall St
Atai Life Sciences Advances Psychedelic Treatments in Q3 2024 - TipRanks
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - The Manila Times
Atai Life Sciences N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
atai Life Sciences Advances Psychedelic Pipeline as FDA Clears DMT Depression Treatment | ATAI Stock News - StockTitan
374Water And 2 Other Promising US Penny Stocks To Watch - Simply Wall St
Are ATAI Life Sciences N.V.’shares a good deal? - US Post News
Insider Sale Alert: ATAI Life Sciences N.V. [ATAI] – Is it Time to sell? - Knox Daily
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit - StockTitan
Selling Buzz: ATAI Life Sciences N.V. [ATAI] 10% Owner ATAI Life Sciences N.V. sells 2,660,000 shares of the company - Knox Daily
ATAI Life Sciences N.V. (ATAI)’s results reveal risk - US Post News
Maxim Group gives a Buy recommendation for ATAI Life Sciences N.V. (ATAI) - Knox Daily
ATAI Life Sciences completes acquisition of IntelGenx Corp. - Investing.com India
ATAI Life Sciences completes acquisition of IntelGenx Corp. By Investing.com - Investing.com South Africa
10% Owner ATAI Life Sciences N.V. sale 2,660,000 shares of ATAI Life Sciences N.V. [ATAI] - Knox Daily
ATAI Life Sciences N.V. (ATAI) stock analysis: A comprehensive overview - US Post News
Trading Day Review: ATAI Life Sciences N.V. (ATAI) Loses Momentum, Closing at 1.16 - The Dwinnex
A History of Outperforming Analyst Forecasts and Beating the Odds: ATAI Life Sciences N.V. (ATAI) - SETE News
Maxim Group Upgrades ATAI Life Sciences N.V. (ATAI) to a Buy from a Hold - Knox Daily
Life Sciences N.V. Atai Sells 2,660,000 Shares of COMPASS Pathways plc (NASDAQ:CMPS) Stock - MarketBeat
Atai Life Sciences executives sell shares valued at $16 million - Investing.com India
Deeper Dive: Understanding ATAI Life Sciences N.V. (ATAI) Through its Various Ratios - The Dwinnex
ATAI Life Sciences N.V. (ATAI) deserves closer scrutiny - US Post News
ATAI Life Sciences N.V. [ATAI] Shares Fall Approximately -7.81% Over the Year - Knox Daily
TWKS SPECIAL ALERT: Thoughtworks Shareholders Seeking More Than $4.40 Per Share Contact Julie & Holleman Regarding Sale to Apax - PR Newswire
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
T2 Biosystems Achieves Successful Defense of Patent for - GlobeNewswire
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology - StockTitan
Magic mushroom market set to go gangbusters, Irish researcher says - Mugglehead
ATAT’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
Athira shifts focus to ALS drug after Alzheimer’s flop - The Pharma Letter
Australian Clinical Labs Shareholder Stake Shifts - TipRanks
(ATAT) Trading Advice - Stock Traders Daily
T2 Biosystems director sells shares worth $133 - Investing.com India
Atour Lifestyle Holdings Ltd ADR (ATAT) is looking forward to a strong quarter - SETE News
Atour Lifestyle Holdings Limited (NASDAQ:ATAT) Short Interest Down 8.3% in August - MarketBeat
Alzheimer’s drug developer Actinogen rattles the tin - The Australian Financial Review
Substantial Stake Acquired in Australian Clinical Labs - TipRanks
Cat defies the odds to survive after being born with two faces - MSN
ATAI Life Sciences N.V. [ATAI] See Remarks makes an insider sale of 151,303 shares worth $0.29 million. - Knox Daily
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients - GlobeNewswire
Two-faced kitten in Phetchabun leaves locals feline lottery curious - Thaiger
Monitoring ATAI Life Sciences N.V. (ATAI) after recent insider movements - Knox Daily
Market Watch Highlights: ATAI Life Sciences N.V. (ATAI) Ends on an Upturn Note at 1.24 - The Dwinnex
ATAI Life Sciences N.V. [ATAI] Insider Activity: An Update for Investors - Knox Daily
ATAI Life Sciences N.V. (ATAI)’s stock chart: A technical perspective - US Post News
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Psychedelic Drugs Market to Grow by USD 1.37 Billion from 2024-2028, Driven by Increasing Mental Health Disorders, Report Highlights AI's Impact on the Market LandscapeTechnavio - The Malaysian Reserve
Psychedelic Stock Deep Dive: Atai Life Sciences (ATAI) (NASDAQ:ATAI) - Seeking Alpha
H.C. Wainwright raises outlook on atai Life Sciences stock as pipeline progresses - Investing.com
Market Momentum: ATAI Life Sciences N.V. (ATAI) Registers a -1.56 Decrease, Closing at 1.26 - The Dwinnex
ATAI Life Sciences N.V. (ATAI) presents a great opportunity, but the stock is slightly undervalued - US Post News
ATAI Life Sciences N.V. (ATAI) may enjoy gains as insiders got busy in the recent days - Knox Daily
ATAI Life Sciences N.V. [NASDAQ: ATAI] Sees Decrease in Stock Value - Knox Daily
Can you still get a good price for ATAI Life Sciences N.V. (ATAI) Shares at this point? - US Post News
Analyzing ATAI Life Sciences N.V. (ATAI) After Recent Trading Activity - Knox Daily
Financial Metrics Unveiled: ATAI Life Sciences N.V. (ATAI)’s Key Ratios in the Spotlight - The Dwinnex
Holdings of ATAI Life Sciences N.V. (ATAI) are aligned with the stars - SETE News
How the next psychedelics companies believe they can avoid Lykos’ fate - BioCentury
The Psychology of ATAI Life Sciences N.V. Inc. (ATAI) Price Performance: Understanding Market Sentiment - The InvestChronicle
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):